164 related articles for article (PubMed ID: 37689278)
1. Up-to-date molecular medicine strategies for management of ocular surface neovascularization.
Yang Y; Zhong J; Cui D; Jensen LD
Adv Drug Deliv Rev; 2023 Oct; 201():115084. PubMed ID: 37689278
[TBL] [Abstract][Full Text] [Related]
2. Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.
Kim BH; Lee J; Choi JS; Park DY; Song HY; Park TK; Cho CH; Ye SK; Joo CK; Koh GY; Kim TY
Br J Pharmacol; 2015 Aug; 172(15):3875-89. PubMed ID: 25917462
[TBL] [Abstract][Full Text] [Related]
3. An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.
Zhang C; Yin Y; Zhao J; Li Y; Wang Y; Zhang Z; Niu L; Zheng Y
Int J Nanomedicine; 2022; 17():4911-4931. PubMed ID: 36267540
[TBL] [Abstract][Full Text] [Related]
4. Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases.
Bock F; Maruyama K; Regenfuss B; Hos D; Steven P; Heindl LM; Cursiefen C
Prog Retin Eye Res; 2013 May; 34():89-124. PubMed ID: 23348581
[TBL] [Abstract][Full Text] [Related]
5. [Antiangiogenic therapy at the ocular surface: when, what and why?].
Bock F; Regenfuss B; Cursiefen C
Ophthalmologe; 2011 Mar; 108(3):230-6. PubMed ID: 21271256
[TBL] [Abstract][Full Text] [Related]
6. [Molecular aspects of corneal neovascularization].
Krawczyk P; Ambroziak AM; Szaflik JP
Klin Oczna; 2014; 116(3):210-4. PubMed ID: 25799787
[TBL] [Abstract][Full Text] [Related]
7. Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway.
Shen M; Zhou XZ; Ye L; Yuan Q; Shi C; Zhu PW; Jiang N; Ma MY; Yang QC; Shao Y
Int J Mol Med; 2018 Aug; 42(2):769-778. PubMed ID: 29717775
[TBL] [Abstract][Full Text] [Related]
8. Corneal neovascularization.
Nicholas MP; Mysore N
Exp Eye Res; 2021 Jan; 202():108363. PubMed ID: 33221371
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization.
Barry Z; Park B; Corson TW
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751576
[TBL] [Abstract][Full Text] [Related]
10. Available Therapeutic Options for Corneal Neovascularization: A Review.
Drzyzga Ł; Śpiewak D; Dorecka M; Wyględowska-Promieńska D
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791518
[TBL] [Abstract][Full Text] [Related]
11. Anti-VEGF Treatment in Corneal Diseases.
Giannaccare G; Pellegrini M; Bovone C; Spena R; Senni C; Scorcia V; Busin M
Curr Drug Targets; 2020; 21(12):1159-1180. PubMed ID: 32189591
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroids as antiangiogenic agents.
Oliver A; Ciulla TA
Ophthalmol Clin North Am; 2006 Sep; 19(3):345-51, v. PubMed ID: 16935209
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.
Han YS; Lee JE; Jung JW; Lee JS
Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):541-8. PubMed ID: 18953554
[TBL] [Abstract][Full Text] [Related]
14. Apatinib-loaded nanoparticles suppress vascular endothelial growth factor-induced angiogenesis and experimental corneal neovascularization.
Lee JE; Kim KL; Kim D; Yeo Y; Han H; Kim MG; Kim SH; Kim H; Jeong JH; Suh W
Int J Nanomedicine; 2017; 12():4813-4822. PubMed ID: 28740387
[TBL] [Abstract][Full Text] [Related]
15. Ocular antisense oligonucleotide delivery by cationic nanoemulsion for improved treatment of ocular neovascularization: an in-vivo study in rats and mice.
Hagigit T; Abdulrazik M; Valamanesh F; Behar-Cohen F; Benita S
J Control Release; 2012 Jun; 160(2):225-31. PubMed ID: 22138070
[TBL] [Abstract][Full Text] [Related]
16. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization.
Chaoran Z; Zhirong L; Gezhi X
Graefes Arch Clin Exp Ophthalmol; 2011 Oct; 249(10):1493-501. PubMed ID: 21574021
[TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF therapy with bevacizumab for anterior segment eye disease.
Hosseini H; Nowroozzadeh MH; Salouti R; Nejabat M
Cornea; 2012 Mar; 31(3):322-34. PubMed ID: 22157572
[TBL] [Abstract][Full Text] [Related]
18. A robust model for simultaneously inducing corneal neovascularization and retinal gliosis in the mouse eye.
Paranthan RR; Bargagna-Mohan P; Lau DL; Mohan R
Mol Vis; 2011; 17():1901-8. PubMed ID: 21850164
[TBL] [Abstract][Full Text] [Related]
19. Recent drug therapies for corneal neovascularization.
Liu X; Wang S; Wang X; Liang J; Zhang Y
Chem Biol Drug Des; 2017 Nov; 90(5):653-664. PubMed ID: 28489275
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model.
Li X; Zhou Q; Hanus J; Anderson C; Zhang H; Dellinger M; Brekken R; Wang S
Mol Pharm; 2013 Jan; 10(1):307-18. PubMed ID: 23186311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
